International: +1-347-960-6455
Post-Traumatic Stress Disorder (PTSD) Therapeutics Pipeline to Witness Significant Growth due to Positive Clinical Results in the Coming Years

According to a new research report Post-Traumatic Stress Disorder (PTSD) Therapeutics – Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments” published by Pharma Proff, PTSD therapeutics currently exhibits a proliferating pipeline with 10+ therapeutic candidates.

PTSD Therapeutics Pipeline Insights

Post-Traumatic Stress Disorder (PTSD) is a serious condition that occurs in people who have experienced or witnessed a life-threatening event, such as a natural disaster, serious accident, terrorist incident, sudden death of a loved one, war, rape, or other violent personal assault. The fear due to such incidents triggers many split-second changes in the body, which protect the body in adverse situations.

PTSD is not diagnosed unless the symptoms last for at least one month. In order to be diagnosed with PTSD, a person must have three different types of symptoms: re-experiencing symptoms, avoidance and numbing symptoms, and arousal symptoms. Cognitive behavioral therapy (CBT) and family therapy are some of the therapies used to treat PTSD. ZOLOFT (by Pfizer Inc.), a selective serotonin reuptake inhibitor (SSRI), is being used for the treatment of PTSD.

Insights on Pipeline Segments

According to the research findings, majority of the pipeline drug candidates are being developed to be administered by oral route. It has been observed that the oral route of medication is convenient, available in delayed or rapid release formulation, less risk of systemic infections, and inexpensive in nature, and also provides improved patient’s compliance. Administration of therapeutics for PTSD through oral route has shown promising results in clinical studies.

Positive Clinical Trial Results are Expected to Drive the PTSD Therapeutics Pipeline Advancements

Companies that are involved in developing therapeutics for PTSD have shown positive clinical results in the various phases of drug development. For instance, BNC210, a negative allosteric modulator of the A7 nicotinic acetylcholine receptor, is being developed by Bionomics Limited to treat patients with PTSD. The results from the phase II trial of BNC210 showed that BNC210 was safe and well tolerable in patients with PTSD.

Browse Detailed Report at:

Strategic Advancements Play a Pivotal Role in the Development of PTSD Therapeutics

H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co. Ltd. (Otsuka) entered into an agreement to develop and commercialize five innovative products in the field of psychiatry and neuroscience. In November 2018, Lundbeck and Otsuka reported positive phase II data from the combination treatment of brexpiprazole and sertraline for the treatment of PTSD.

Bionomics Limited, Pfizer Inc., India Globalization Capital Inc., Therapade Technologies LLC, Axim Biotechnologies Inc., H. Lundbeck A/S, and Otsuka Pharmaceutical Co. Ltd. are some of the major companies involved in the development of drug candidates for the treatment of PTSD.

PTSD Therapeutics Pipeline Analysis

  • By Phase
  • By Molecule Type
  • By Route of Administration
  • By Company

The report comprises detailed pipeline analysis of therapeutics being developed for the treatment of PTSD. Comprehensive insights on the pipeline products have been provided, with special focus on strategic developments of key players, information on drug licensing, designations, financing, and grants, technological advancements, patents, and upcoming conferences. In addition, the report highlights the winning strategies of companies involved in the PTSD therapeutics development. Detailed regulatory approval procedures in the U.S., Europe, and Japan are also provided in the report. Furthermore, the report contains competitive analysis and extensive information on monotherapies, combination therapies, targets and mechanisms of action, and drug origin with respect to PTSD.